Haleon upgraded to Chubby from Equal Weight at Barclays
Barclays analyst Iain Simpson upgraded Haleon to Chubby from Equal Weight with a worth goal of 360 GBp, up from 298 GBp, after after a U.S. federal decide rejected the scientific proof behind greater than 5,000 lawsuits claiming heartburn drug Zantac may cause most cancers. Haleon is “investable once more” now that the Zantac state of affairs is “considerably derisked,” Simpson tells buyers in a analysis be aware.
Revealed first on TheFly
See Insiders’ Sizzling Shares on TipRanks >>
Learn Extra on HLN:
